Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).


Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO) Criteria in patients with hypermutated recurrent glioblastoma. SECONDARY OBJECTIVES: I. Estimate the overall survival distribution, median survival, and one-year survival rate of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab. II. Estimate the progression-free survival distribution and median progression-free survival of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab. III. Determine the adverse event profile of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab. EXPLORATORY OBJECTIVES: I. Test whether PD-L1 or immunologic infiltrate in the tumor microenvironment are associated with objective tumor response, overall survival, progression-free survival, tumor mutational burden, or rates of grade 3 or higher adverse events. II. Test whether MGMT status, microsatellite instability (MSI) status, mutational signatures, or amount of tumor mutational burden (TMB) including germline analysis are associated with objective tumor response, overall survival, progression-free survival, or rates of grade 3 or higher adverse events. III. Evaluate associations between exome and transcriptome gene levels with objective tumor response, overall survival, progression-free survival, rates of grade 3 or higher adverse events. IV. Evaluate associations between the gut microbiome and objective tumor response. V. Response rate using immunotherapy (i)RANO. OUTLINE: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo magnetic resonance imaging (MRI) throughout the study. After completion of study treatment, patients without disease progression are followed every 8 weeks until disease progression, then every 3 months for up to 3 years. Patients with disease progression after completion of study treatment are followed every 3 months for up to 3 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04145115
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Suspended
Phase Phase 2
Start date December 24, 2020
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05941234 - Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma N/A
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT06160596 - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Recruiting NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Not yet recruiting NCT04945148 - Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide Phase 2
Not yet recruiting NCT05842746 - Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma Phase 2
Not yet recruiting NCT06419946 - Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma Phase 3
Completed NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Recruiting NCT06418113 - Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma Phase 1
Recruiting NCT05326334 - THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
Recruiting NCT05375318 - BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
Not yet recruiting NCT06359379 - Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Phase 2
Recruiting NCT06095375 - Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients Phase 1
Recruiting NCT05879367 - Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT05759195 - Biomolecular Analysis for Predicting Response to Regorafenib N/A
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06273176 - The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)